Neuracle

Company CN Private Editorial profile Website

Profile

Shanghai BCI maker whose semi-invasive NEO implant (with Tsinghua) won the world's first commercial approval for an invasive-class BCI (NMPA, 2026).

Editorial profile — compiled by us from public sources.

Headquarters: Shanghai, China

Current standings

Standings and milestones are always verified by us against primary sources, regardless of who manages the profile.

—

Roadmap & milestones

World's first commercial invasive-BCI approval

2026-03

Neuracle / NMPA (China)

China's NMPA cleared Neuracle's coin-sized NEO implant (developed with Tsinghua) for commercial sale to restore hand function after spinal-cord injury — the first invasive-class BCI approved for market anywhere, ahead of Neuralink.

Press release · 2026-03

More in Brain-Computer Interfaces

Neuralink

Synchron

Precision Neuroscience

Paradromics

Blackrock Neurotech

Science Corporation